Print PagePrint Page
E-mail PageE-mail Page
RSS FeedsRSS Feeds
X
Share Page
E-mail AlertsE-mail Alerts
IR ContactsIR Contacts

2015 Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
12/02/15vTv Therapeutics Announces Larry Altstiel to Serve As Chief Medical Officer
Brings Decades of Pharmaceutical Research and Management Experience, Including Serving in Senior Roles at Pfizer and Eli Lilly Company HIGH POINT, N.C.--(BUSINESS WIRE)--Dec. 2, 2015-- vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that Larry Altstiel has joined the company as Chief Medical Officer. Altstiel brings decades of pharmaceutical industry experience and medical expertise to vTv, including serving in senior research and management role... 
Printer Friendly Version
11/24/15vTv Therapeutics to Participate in Fireside Chat at Piper Jaffray 27th Annual Healthcare Conference
HIGH POINT, N.C.--(BUSINESS WIRE)--Nov. 24, 2015-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease (AD) and diabetes, announced that Stephen Holcombe, President and CEO, Aaron Burstein, SVP, Clinical Development, and Carmen Valcarce, SVP, Chief Scientific Officer, will participate in an analyst-led fireside chat at 4:00 p... 
Printer Friendly Version
11/13/15vTv Therapeutics to Present at Stifel 2015 Healthcare Conference
HIGH POINT, N.C.--(BUSINESS WIRE)--Nov. 13, 2015-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease (AD) and diabetes, today announced that Stephen Holcombe, President and CEO, Aaron Burstein, SVP, Clinical Development, and Carmen Valcarce, SVP, Chief Scientific Officer, will be presenting a corporate and clinical overview... 
Printer Friendly Version
11/12/15vTv Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2015
HIGH POINT, N.C.--(BUSINESS WIRE)--Nov. 12, 2015-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease (AD) and diabetes, today reported financial results for the third quarter of 2015 and provided an update on recent developments. “I’m pleased to report that vTv has had a highly productive quarter and 2015. We... 
Printer Friendly Version
10/22/15vTv Therapeutics to Present at the 8th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
HIGH POINT, N.C.--(BUSINESS WIRE)--Oct. 22, 2015-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today announced that Dr. Marwan Sabbagh from the Barrow Neurological Institute, Principal Investigator for the ongoing Phase 3 Steadfast trial, will be presenting an evaluation of the Phase 2b safety study of ... 
Printer Friendly Version
09/28/15CORRECTING and REPLACING vTv Therapeutics to Present at Ladenburg Thalmann 2015 Healthcare Conference
HIGH POINT, N.C.--(BUSINESS WIRE)--Sep. 28, 2015-- First paragraph, second sentence of release dated September 23, 2015, should read: The presentation will take place at 2:00 pm EDT on Tuesday, September 29 at the Sofitel Hotel in New York City (instead of: The presentation will take place at 2:30 pm EDT on Tuesday, September 29 at the Sofitel Hotel in New York City). The corrected release reads:  vTv THERAPEUTICS TO PRESENT AT LAD... 
Printer Friendly Version
09/23/15vTv Therapeutics to Present at Ladenburg Thalmann 2015 Healthcare Conference
HIGH POINT, N.C.--(BUSINESS WIRE)--Sep. 23, 2015-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today announced that Stephen Holcombe, President and CEO, and Aaron Burstein, SVP, Clinical Development, will be presenting a corporate overview at the Ladenburg Thalmann 2015 Healthcare Conference. The present... 
Printer Friendly Version
07/29/15vTv Therapeutics Inc. Announces Pricing of Initial Public Offering
HIGH POINT, N.C.--(BUSINESS WIRE)--Jul. 29, 2015-- vTv Therapeutics Inc. (the “Company”) (Nasdaq:VTVT) announced today the pricing of its initial public offering of 7,812,500 shares of its Class A common stock at a price to the public of $15.00 per share. All of the shares are being offered by the Company. In addition, the Company has granted the underwriters an option to purchase up to an additional 1,171,875 shares of Class A common stock. The shares o... 
Printer Friendly Version
07/20/15vTv Therapeutics Inc. Announces Launch of Initial Public Offering
vTv Therapeutics Inc. (the “Company”) today announced the launch of its initial public offering in the United States of 7,812,500 shares of its Class A common stock. The initial public offering price is currently expected to be between $15.00 and $17.00 per share of Class A common stock.  The Company has submitted an application for listing on the NASDAQ Global Market and trading under the ticker symbol “VTVT.”  The underwriters have the option to purchase from the Company up to an add... 
Printer Friendly Version
06/29/15vTv Therapeutics Appoints Rudy Howard as Chief Financial Officer
High Point, North Carolina (June 29, 2015) vTv Therapeutics LLC (vTv), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today announced the appointment of Rudy C. Howard as Chief Financial Officer. Mr. Howard joins the Company with over 30 years of senior management experience, most recently serving as CFO at SciQuest, an international spend management software company. Previously, he s... 
Printer Friendly Version
06/15/15vTv Therapeutics Files Registration Statement for Proposed Initial Public Offering
High Point, North Carolina (June 15, 2015) vTv Therapeutics LLC (vTv), a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates, today announced it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of shares of its Class A common stock. Piper Jaffray & Co. and Stifel are acting as joint book running managers for the offe... 
Printer Friendly Version
06/04/15vTv Therapeutics Initiates Patient Dosing in the AGATA Study, a six Month Phase 2 Study Evaluating TTP399, a Liver-selective GlucoKinase Activator, for the Treatment of Type 2 Diabetes
In a 6 Week Phase 2a Study, Treatment Showed Statistically Significant and Clinically Meaningful Reduction in A1c LevelsHigh Point, North Carolina (June 4, 2015) vTv Therapeutics LLC announced today that it has initiated dosing of the AGATA study, a phase 2b clinical trial assessing the efficacy and safety of TTP399, an oral liver-selective Glucokinase Activator (GKA), in patients with type 2 diabetes. In a phase 2a study, TTP399 demonstrated a statistically significant and clinically meaningfu... 
Printer Friendly Version
05/19/15vTv Therapeutics Initiates Pivotal Phase 3 Trial Evaluating Azeliragon for the Treatment of Patients with Mild Alzheimer’s Disease
Completed Phase 2 Trial Showed Positive Results Combating Alzheimer’s Disease High Point, North Carolina (May 19, 2015) vTv Therapeutics LLC (vTv) today announced enrollment of the first patients into STEADFAST (Single Trial Evaluating Alzheimer’s Disease Following Addition to Symptomatic Therapy), vTv’s Phase 3 placebo controlled trial of azeliragon, an oral antagonist of the Receptor for Advanced Glycation Endproducts (RAGE) for treatment of mild Alzheimer’s disease. Phase 3 begins following a... 
Printer Friendly Version
03/05/15TransTech Pharma and Calithera Biosciences Enter Into Worldwide Licensing Agreement for Hexokinase II Inhibitor Program
High Point, North Carolina (March 5, 2015)TransTech Pharma, LLC today announced a global licensing agreement granting Calithera Biosciences, Inc. exclusive world-wide rights to research, develop and commercialize TransTech’s portfolio of hexokinase II inhibitors. TransTech will receive an upfront payment and will be eligible to receive future development and commercialization milestones as well as royalties on sales of approved products.Hexokinase II is the first enzyme in the pathway that enabl... 
Printer Friendly Version